Netherlands-based Pharming Group (Euronext: PHARM) has entered into an exclusive distribution agreement with Cytobioteck, a privately owned Bogota, Colombia-based specialty health care company, for the distribution of Ruconest (recombinant human C1 inhibitor) for the treatment of acute attacks of hereditary angioedema (HAE) in Colombia and Venezuela.
Under the agreement, Cytobioteck will drive all regulatory processes and will purchase its commercial supplies of Ruconest from Pharming at a fixed transfer price. No further terms of the accord were disclosed.
Sijmen de Vries, Pharming’s chief executive, commented: “we are very pleased that Cytobioteck will be engaged in the distribution of Ruconest in Colombia and Venezuela, two countries where a considerable number of patients with HAE have been diagnosed.”
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze